ArticleBMC endocrine disorders2025
Visceral lipid accumulation and lipid accumulation product outperform insulin resistance score for metabolic syndrome prediction in Northern Chinese adults: validation through AUC comparison and decision curve analysis.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations of Five Insulin Resistance-Related Indices With Gout Risk in the 2007-2018 NHANES Cross-Sectional Study.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS) significantly elevates the risk of diabetes and cardiovascular disease. While insulin resistance (IR) underpins MetS pathogenesis, practical biomarkers for population screening remain limited. The metabolic score for IR (METS-IR), lipid accumulation product (LAP) and visceral adiposity index (VAI) are highly sensitive and specific biomarkers of IR, which require comparative validation.
objectiveTo compare LAP, VAI, and METS-IR index for predicting MetS with sex-stratified analysis.
methodsThe physiological characteristics and blood biochemistry data collected from 2821 patients during an annual health check-up were analyzed. Participants were assigned to MetS group (≥3 MetS conditions), pre-Mets group (1-2 Mets components) or control group (0 component) based on IDF/AHA/NHLBI 2009 criteria and were further stratified by sex. The predictive value and clinical usefulness of the LAP, VAI, and METS-IR were evaluated by receiver operating characteristic (ROC) curve and decision curve analysis (DCA).
resultsLAP, VAI, and METS-IR levels were significantly elevated in the MetS group (P < 0.05) and strongly correlated with MetS components. ROC analysis revealed LAP as the superior predictor in the total cohort (AUC: 0.904 [95% CI: 0.888-0.920]) and females (AUC: 0.949 [95% CI: 0.921-0.976]), while VAI performed best in males (AUC: 0.863 [95% CI: 0.840-0.886]). DCA confirmed the superior clinical utility of LAP and VAI over METS-IR across subgroups.
conclusionThis large-scale validation establishes LAP and VAI as superior, sex-specific predictors of MetS compared to METS-IR. LAP is optimal overall and in women, while VAI is optimal in men. Their reliance on standard clinical measurements establishes them as practical tools for metabolic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.